Device Therapy in Cardiac Sarcoidosis: Current Review, Challenges, and Future Prospects

Area of Science:

• Cardiology
• Immunology
• Medical Devices

Background:

• Sarcoidosis is an inflammatory disease affecting multiple organs, with cardiac involvement posing significant diagnostic and therapeutic challenges.
• Cardiac sarcoidosis can lead to severe arrhythmias and sudden cardiac death (SCD), necessitating effective preventative strategies.
• Current guidelines for implantable cardioverter-defibrillators (ICDs) may not cover all at-risk cardiac sarcoidosis patients.

Purpose of the Study:

• To explore the challenges in diagnosing and managing cardiac sarcoidosis, particularly concerning SCD risk.
• To evaluate the potential of novel device therapies, including subcutaneous ICDs (S-ICDs) and leadless pacing, for managing cardiac sarcoidosis.
• To highlight the need for personalized approaches in treating cardiac sarcoidosis patients at risk of SCD.

Main Methods:

• Review of current diagnostic criteria and treatment guidelines for cardiac sarcoidosis.
• Analysis of the limitations and complications associated with traditional transvenous ICDs in immunosuppressed patients.
• Exploration of the emerging role of S-ICD and leadless pacing, referencing ongoing clinical trials.

Main Results:

• Cardiac sarcoidosis diagnosis is complex, requiring advanced imaging and histology.
• Traditional ICDs carry risks, and not all patients meet implantation criteria, leaving a gap in care.
• S-ICDs offer an alternative to transvenous devices, mitigating vascular and infection risks, but have limitations like inappropriate shocks and lack of pacing.

Conclusions:

• Leadless pacing combined with S-ICD presents a promising, personalized therapeutic strategy for cardiac sarcoidosis patients.
• This novel approach may address the unmet needs of cardiac sarcoidosis patients underserved by conventional device therapies.
• Further clinical research is crucial to establish the safety and efficacy of combined S-ICD and leadless pacing for SCD prevention in this population.